Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity

Journal of Investigative Dermatology

Volumn 132, Issue 6, 2012, Pages 1645-1655

  Fujita, Hideki ^a   Suárez Farĩas, Mayte ^a   Mitsui, Hiroshi ^a   Gonzalez, Juana ^a   Bluth, Mark J ^a   Zhang, Shali ^b   Felsen, Diane ^c   Krueger, James G ^a   Carucci, John A ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LANGERHANS CELL; LYMPHOCYTE PROLIFERATION; POLARIZATION; PRIORITY JOURNAL; SKIN CARCINOMA; SUPERNATANT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 84862799106     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.34     Document Type: Article

References (47)

1. Aldemir H, Prod'homme V, Dumaurier MJ et al. (2005) Cutting edge: lectinlike transcript 1 is a ligand for the CD161 receptor. J Immunol 175:7791-5 (Pubitemid 41798337)
2. Almand B, Clark JI, Nikitina E et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678-89 (Pubitemid 32038493)
3. Almand B, Resser JR, Lindman B et al. (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-66 (Pubitemid 30305068)
4. Banchereau J, Klechevsky E, Schmitt N et al. (2009) Harnessing human dendritic cell subsets to design novel vaccines. Ann NY Acad Sci 1174:24-32
5. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296-306 (Pubitemid 40516155)
6. Banchereau J, Palucka AK, Dhodapkar M et al. (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitorderived dendritic cell vaccine. Cancer Res 61:6451-8 (Pubitemid 32783251)
7. Bennaceur K, Chapman J, Brikci-Nigassa L et al. (2008) Dendritic cells dysfunction in tumour environment. Cancer Lett 272:186-96
8. Berntsen A, Geertsen PF, Svane IM (2006) Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50: 34-43 (Pubitemid 43850125)
9. Berthier-Vergnes O, Gaucherand M, Peguet-Navarro J et al. (2001) Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells. Br J Cancer 85:1944-51 (Pubitemid 34775333)
10. Bluth MJ, Zaba LC, Moussai D et al. (2009) Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol 129:2451-62
11. Chaput N, Conforti R, Viaud S et al. (2008) The Janus face of dendritic cells in cancer. Oncogene 27:5920-31
12. Curiel TJ, Wei S, Dong H et al. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562-7 (Pubitemid 36597102)
13. Della Bella S, Gennaro M, Vaccari M et al. (2003) Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89:1463-72 (Pubitemid 37386601)
14. Di Nicola M, Carlo-Stella C, Mortarini R et al. (2004) Boosting T cellmediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)- derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res 10:5381-90 (Pubitemid 39100475)
15. El Marsafy S, Bagot M, Bensussan A et al. (2009) Dendritic cells in the skin- potential use for melanoma treatment. Pigment Cell Melanoma Res 22:30-41
16. Enk AH, Jonuleit H, Saloga J et al. (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-16 (Pubitemid 27508890)
17. Ferlazzo G, Wesa A, Wei WZ et al. (1999) Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J Immunol 163: 3597-604 (Pubitemid 29450879)
18. Flacher V, Sparber F, Tripp CH et al. (2009) Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunol Immunother 58:1137-47
19. Fricke I, Gabrilovich DI (2006) Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 35:459-83 (Pubitemid 44266783)
20. Fujita H, Nograles KE, Kikuchi T et al. (2009) Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci USA 106:21795-800
21. Gabrilovich DI, Corak J, Ciernik IF et al. (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483-90 (Pubitemid 27158075)
22. Galan A, Ko CJ (2007) Langerhans cells in squamous cell carcinoma versus pseudoepitheliomatous hyperplasia of the skin. J Cutan Pathol 34: 950-952 (Pubitemid 350131999)
23. Gottfried E, Kreutz M, Mackensen A (2008) Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 19: 65-77 (Pubitemid 351200062)
24. Ishida T, Oyama T, Carbone DP et al. (1998) Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 161:4842-51 (Pubitemid 28492062)
25. Kalinski P, Urban J, Narang R et al. (2009) Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol 5:379-90
26. Maggi L, Santarlasci V, Capone M et al. (2010) CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 40:2174-81
27. Mortarini R, Anichini A, Di Nicola M et al. (1997) Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)- specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57:5534-41 (Pubitemid 28006761)
28. Nestle FO, Alijagic S, Gilliet M et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-32 (Pubitemid 28144092)
29. Nestle FO, Burg G, Fah J et al. (1997) Human sunlight-induced basal-cellcarcinoma- associated dendritic cells are deficient in T cell costimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 150:641-51 (Pubitemid 27073791)
30. Palucka AK, Ueno H, Connolly J et al. (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29:545-57 (Pubitemid 44395279)
31. Perrot I, Blanchard D, Freymond N et al. (2007) Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178:2763-9 (Pubitemid 46333153)
32. Pinzon-Charry A, Maxwell T, Lopez JA (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83:451-61 (Pubitemid 41805745)
33. Ratzinger G, Baggers J, de Cos MA et al. (2004) Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL- 12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol 173: 2780-91 (Pubitemid 39063140)
34. Romani N, Thurnher M, Idoyaga J et al. (2010) Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 88:424-30
35. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-15 (Pubitemid 39273730)
36. Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-47 (Pubitemid 36287518)
37. Shurin MR, Lotze MT (2009) Dendritic cells in cancer emergence of the discipline. In: Dendritic Cells in Cancer. (Shurin MR, Salter RD eds). Springer: New York 11-30
38. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419-26 (Pubitemid 47509552)
39. Stoitzner P, Green LK, Jung JY et al. (2008) Tumor immunotherapy by epicutaneous immunization requires Langerhans cells. J Immunol 180:1991-8
40. Stoitzner P, Sparber F, Tripp CH (2010) Langerhans cells as targets for immunotherapy against skin cancer. Immunol Cell Biol 88:431-7
41. Takahara M, Chen S, Kido M et al. (2009) Stromal CD10 expression, as well as increased dermal macrophages and decreased Langerhans cells, are associated with malignant transformation of keratinocytes. J Cutan Pathol 36:668-74
42. Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26:373-400 (Pubitemid 350115102)
43. Thurner B, Haendle I, Roder C et al. (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-78 (Pubitemid 30002348)
44. Troy AJ, Summers KL, Davidson PJ et al. (1998) Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 4:585-93 (Pubitemid 28193556)
45. Ueno H, Schmitt N, Klechevsky E et al. (2010) Harnessing human dendritic cell subsets for medicine. Immunol Rev 234:199-212
46. Vicari AP, Caux C, Trinchieri G (2002) Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12:33-42 (Pubitemid 34087896)
47. Zou W (2005) Immunosuppressive networkks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-74 (Pubitemid 40488632)